| Ytd | -14.09% | |
| 1y | 180.65% |
| Open | 13.39 | Prev Close | 13.38 | Low | 13.12 | High | 13.59 | Mkt Cap | 1.15B |
| Vol | 184.59K | Avg Vol | 1.43M | EPS | -1.75 | P/E | N/A | Forward P/E | -7.13 |
| Beta | 1.59 | Short Ratio | 12.37 | Inst. Own | 115.81% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 19.60 | 200-d Avg | 18.52 | 1yr Est | 28.50 |
GLUE News
Bank of America Corp DE lifted its stake in Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) by 73.3% du
Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy an
Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free sur
Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutat
Dimensional Fund Advisors LP boosted its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight a
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweig
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Co
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share which missed th
Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascu
Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-s
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and
This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a ye
Monte Rosa Therapeutics, Inc. is a leading biotech in molecular glue degraders, with a $1.45bn valua
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-s
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-st
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight a
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.45 per share versus the Zacks Co
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.45) per share which missed th
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP re
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-st
A GLUE executive disposed of 8,000 shares for a transaction value of approximately $141,000 at a wei
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vi
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vi
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) has been given an average recommendat
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweig
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.55 per share versus the Zacks Co
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.55) per share which missed th
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-
Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a like
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with
Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Ove
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweig
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and
Effective January 7, 2026, Monte Rosa Therapeutics, Inc. (the "Company") terminated the sale
Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology
Monte Rosa revealed positive interim Phase 1 data of MRT-8102. Data showed safety, tolerability, and
GLUE: 42% | Monte Rosa Therapeutics shares are trading higher after the company announced it will pr
In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glu